- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01299090
Prospective Pellevé™ Neck Wrinkle Study
March 28, 2016 updated by: Ellman International
Use of RF device to treat wrinkles of the neck
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective study evaluating the safety and efficacy of two treatments, spaced at 30 day intervals, using the Surgitron® Dual RF™ S5 with the Pellevé™ wrinkle treatment handpiece and Pellevé™ treatment gel for the treatment of neck wrinkles.
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90210
- Moy-Fincher-Chipps Facial Plastics/Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
26 years to 66 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 30-70 years of age
- Subjects with clinical evidence of neck wrinkles moderate to severe in severity as specified by a grade 4-9 on the Fitzpatrick Wrinkle Assessment Scale.
- Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
- Willingness and ability to provide written photo consent and adherence to photography procedures(i.e., removal of jewelry and makeup).
- Willingness and ability to provide written informed consent prior to performance of any study related procedure.
Exclusion Criteria:
- Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
- Subjects who have had prior exposure to any hyaluronic acid, or any other filler, injection for any purpose in the 12 months preceding study enrollment through the duration of the study.
- Subjects who have had prior exposure to any botulinum toxin for rhytids in the treatment area in the 6 months preceding study enrollment through the duration of the study.
- Subjects who have had a prior cosmetic procedure to improve rhytids in the treatment area (i.e.,rhytidectomy, CO2/erbium laser resurfacing, Thermage/Thermacool radiofrequency treatment)within 12 months or who have visible scars that may affect evaluation of response and/or quality of photography.
- Microdermabrasion, or prescription level glycolic acid treatments within 3 months prior to study participation or during the study.
- Active cut, wound, or infection on the skin.
- Oral Isotretinon within the past 12 months.
- Active HSV-1.
- History of keloids or hypertrophic scarring.
- Existing or history of skin malignancy in the treatment area during the past 12 months.
- Existing or history of skin disease in the treatment area during the past 12 months.
- History of collagen or vascular disease.
- Subjects who have implantable pacemaker, automatic implantable defibrillator/ cadioversor (AICD), or any other implantable electric device.
- Subjects who have used, within 30 days, any medication that can cause dermal hypersensitivity or affect skin characteristics.
- History of autoimmune disease.
- History of any disease that inhibits pain sensation.
- History of Diabetes I or II.
- Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
- Subjects who anticipate the need for surgery or overnight hospitalization during the study.
- Subjects who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment or unreliability.
- Enrollment in any active study involving the use of investigational devices or drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment Group
All subjects enrolled were in the treatment group.
|
two treatments spaced 30 days apart
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment
Time Frame: 90 days post treatment
|
Three independent investigators blinded to photography time points will perform retrospective evaluations of photography from all visits using the 9-point Fitzpatrick Wrinkle Assessment Scale for assessment of neck and facial wrinkles at the culmination of the study. The measurement is for percentage of patients who showed improvement |
90 days post treatment
|
|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time Frame: 90 days post treatment
|
The rate of adverse events will be assessed throughout the duration of the study
|
90 days post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lisa Chipps, MD, Moy-Fincher-Chipps Facial Plastics/Dermatology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
February 4, 2011
First Submitted That Met QC Criteria
February 16, 2011
First Posted (Estimate)
February 18, 2011
Study Record Updates
Last Update Posted (Estimate)
April 27, 2016
Last Update Submitted That Met QC Criteria
March 28, 2016
Last Verified
March 1, 2016
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial and Neck Rhytides
-
AllerganCompletedFacial Rhytides | Glabellar RhytidesUnited States, Belgium, Germany, United Kingdom
-
Instituto de Oftalmología Fundación Conde de ValencianaCompletedFacial Aging | Facial Wrinkles and Rhytides ReductionMexico
-
AllerganCompletedFacial RhytidesArgentina
-
AllerganCompletedFacial RhytidesCanada
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedFacial RhytidesUnited States
-
Apyx MedicalCompleted
-
AllerganCompleted
-
ChinaNormCompleted
-
InvasixCompletedFacial Wrinkles and Rhytides ReductionCanada
-
AllerganCompletedGlabellar Frown Lines | Facial RhytidesCanada
Clinical Trials on Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator
-
Ellman InternationalCompletedAppearance of Facial WrinklesUnited States